Quick Navigation

Dose Calculator Complete Guide Available Brands Click Table

mounjaro® CALCULATOR

*Each pen contains 60 total clicks

Which Mounjaro® pen do you have?

10
clicks
Schedule now (teleconsult)
⚠️ IMPORTANT NOTICE: This calculator is an educational tool developed for teaching and informational purposes. The information provided does NOT replace professional medical care. Always consult your doctor before starting, changing, or stopping any treatment with tirzepatide (Mounjaro). Improper use of this medication can cause serious side effects. Responsibility for the use of this information lies exclusively with the user.

Complete Mounjaro Click Table

Desired Dose7.5mg Pen10mg Pen12.5mg Pen15mg Pen
2.5 mg20 clicks15 clicks12 clicks10 clicks
5 mg40 clicks30 clicks24 clicks20 clicks
7.5 mg60 clicks45 clicks36 clicks30 clicks
10 mg—60 clicks48 clicks40 clicks
12.5 mg——60 clicks50 clicks
15 mg———60 clicks

Note: Each Mounjaro pen contains 60 total clicks. The symbol "—" indicates that the desired dose exceeds the pen's capacity.

Mounjaro (Tirzepatide): Complete Guide

IMPORTANT NOTICE: This content is informational and does not replace an individualized medical evaluation. Always consult a healthcare professional.

Mounjaro® (tirzepatide) is an innovation in the management of type 2 diabetes and, in some countries, also in weight management. It is a dual agonist of the GLP-1 and GIP receptors, promoting better blood glucose regulation and supporting weight loss.

What is Mounjaro?

Mounjaro® is the brand name of tirzepatide, developed by Eli Lilly. It differs from other GLP-1 agonists in that it also acts on the GIP receptor, producing additional effects on metabolism and appetite control.

Main Benefits

  • Significant reduction in glycated hemoglobin (HbA1c) in type 2 diabetes
  • Significant weight loss, including in people without diabetes
  • Possible reduction in cardiovascular risk (in clinical studies)
  • Convenient weekly dosing with prefilled pens

Indications

  • Type 2 diabetes, as an adjunct to diet and exercise
  • Weight management (in countries where approved for this indication)

Doses and Presentations

Mounjaro® is available in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg pens. Your doctor will determine the dose progression according to tolerance and response.

Typical Progression Table

WeekDose (mg)Note
1-42,5Starting dose for adaptation
5-85If tolerated
9-127,5If needed
13-1610If needed
17-2012,5If needed
21+15Maximum dose
Dose splitting (adjusting by clicks) is considered off-label and should be done only under medical supervision.

Side Effects

  • Nausea
  • Vomiting
  • Diarrhea
  • Constipation
  • Loss of appetite
  • Injection site reactions

Serious effects (rare): pancreatitis, hypoglycemia, diabetic retinopathy, thyroid C-cell tumors (under investigation).

Contraindications

  • History of medullary thyroid carcinoma or MEN 2 syndrome
  • Pregnancy and breastfeeding (not recommended)
  • Under 18 years of age (safety not established)

Schedule your appointment with Dr. Diegomaier Nunes for an individualized evaluation.

Schedule via WhatsApp

Tirzepatide Brands in Brazil and Worldwide

1. Available Brands

Country/RegionBrand NameMain IndicationRegulatory Status
BrazilMounjaroType 2 diabetes, obesityApproved by Anvisa
United StatesMounjaroType 2 diabetesApproved by the FDA
ZepboundObesity and overweightApproved by the FDA
EuropeMounjaroType 2 diabetes, obesityApproved by the EMA
United KingdomMounjaroType 2 diabetes, obesityApproved by NICE

2. Tirzepatide Brands in Brazil

  • Mounjaro (Eli Lilly):
    • Approved by Anvisa for the treatment of type 2 diabetes since September 2023 and, since June 2025, also for obesity and overweight with comorbidities.
    • Indications:
      • Type 2 diabetes: as an adjunct to diet and exercise
      • Obesity: for adults with BMI ≥ 30, or BMI ≥ 27 with at least one associated comorbidity (e.g., hypertension, dyslipidemia, prediabetes)
  • Zepbound is not yet approved or available in Brazil, and Anvisa's review is pending.

3. Tirzepatide Brands Outside Brazil

  • United States:
    • Mounjaro: approved for type 2 diabetes
    • Zepbound: approved for obesity and overweight by the FDA since November 2023
  • Europe:
    • Mounjaro: approved for type 2 diabetes and, in some countries, also for obesity
  • United Kingdom:
    • Mounjaro: approved for use in the NHS (public health service) for type 2 diabetes and obesity, with specific usage recommendations

4. Explanation of Anvisa Approval

  • Mounjaro is the only tirzepatide brand approved by Anvisa in Brazil, initially for type 2 diabetes and, since June 2025, also for obesity and overweight with comorbidities.
  • Zepbound (also from Eli Lilly), approved in the US for obesity, has not yet been approved by Anvisa for sale in Brazil.

5. Summary of Indications

  • Mounjaro (Brazil, US, Europe): type 2 diabetes and, more recently, obesity
  • Zepbound (US): obesity and overweight, not approved in Brazil
Practical summary: In Brazil, only Mounjaro (Eli Lilly) is approved by Anvisa for type 2 diabetes and, since June 2025, also for obesity. Zepbound, approved in the US for obesity, is not yet available in Brazil. Both brands belong to Eli Lilly and contain tirzepatide as the active ingredient.

Sources and References

Tirzepatide in Brazil: brand name and indications

Brand nameManufacturerFormIndication approved in Brazil
Mounjaro®Eli LillyPen, once a weekType 2 diabetes (since 2023) and chronic weight management in adults with BMI ≥30, or ≥27 with a comorbidity (since June 2025)
Zepbound®Eli LillyPen, once a weekName used in the United States for tirzepatide in the treatment of obesity

Brand names appear here only so you can recognize the medication mentioned on the label, in prescriptions, and in the news. This is not a brand recommendation or an incentive to buy: the choice of medication and dose is an individual medical decision.

Tirzepatide doses according to the label

StepWeekly doseLabel rule
Weeks 1 to 42.5 mgStarting dose, for adaptation
From week 55 mgFirst possible maintenance dose
If needed7.5 · 10 · 12.5 mgIncreases of 2.5 mg after at least 4 weeks on the current dose
Maximum dose15 mgDo not exceed 15 mg per week

The maintenance doses listed on the label are 5, 10 or 15 mg. For weight management, if weight loss does not reach at least 5% in 6 months at the highest tolerated dose, the label advises reassessing whether to continue.

Doses reproduced from the Anvisa-approved label, for educational purposes. The pace of increase may be slower depending on tolerance, and the right dose is determined at the appointment. Do not adjust doses on your own.

What the main tirzepatide studies have shown

Average results from phase 3 studies. These are group averages: each person's response varies.

StudyParticipantsMain resultSource (DOI)
SURMOUNT-1
Jastreboff et al., NEJM, 2022		2,539 adults with obesity or overweight with a comorbidity, without diabetes; 72 weeks−15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) vs −3.1% with placebo10.1056/NEJMoa2206038
SURMOUNT-2
Garvey et al., Lancet, 2023		938 adults with obesity and type 2 diabetes; 72 weeks−12.8% (10 mg) and −14.7% (15 mg) vs −3.2% with placebo10.1016/S0140-6736(23)01200-X
SURMOUNT-3
Wadden et al., Nature Medicine, 2023		579 adults who had already lost ≥5% with intensive lifestyle changesAdditional loss of 18.4% vs gain of 2.5% with placebo10.1038/s41591-023-02597-w
SURMOUNT-4
Aronne et al., JAMA, 2024		670 adults who lost 20.9% in 36 weeksThose who continued lost an additional 5.5%; those who stopped regained 14.0%10.1001/jama.2023.24945
SURMOUNT-5
Aronne et al., NEJM, 2025		751 adults with obesity, without diabetes; tirzepatide vs semaglutide−20.2% with tirzepatide vs −13.7% with semaglutide in 72 weeks10.1056/NEJMoa2416394
SURPASS-2
Frías et al., NEJM, 2021		People with type 2 diabetes; tirzepatide vs semaglutide 1 mgGreater reduction in HbA1c (−2.01 to −2.30 vs −1.86 points) and in weight with tirzepatide10.1056/NEJMoa2107519
SURMOUNT-OSA
Malhotra et al., NEJM, 2024		Adults with moderate-to-severe obstructive sleep apnea and obesityDrop of 25 to 29 events per hour in the apnea index vs about 5 with placebo10.1056/NEJMoa2404881
SUMMIT
Packer et al., NEJM, 2025		731 adults with heart failure with preserved ejection fraction and obesityCardiovascular death or worsening heart failure: 9.9% vs 15.3% with placebo10.1056/NEJMoa2410027

In SURMOUNT-4, people who stopped tirzepatide regained a good part of the weight they had lost. Obesity treatment is long-term and works best together with diet, physical activity, and follow-up care.

Read also

Need personalized medical guidance?

Schedule your teleconsult from the comfort of your home. Individualized medical evaluation for guidance on the safe and effective use of Mounjaro.

Schedule Teleconsult